Published in Am J Nephrol on September 02, 2017
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93
Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J (2006) 4.55
Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med (2014) 4.13
Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med (2004) 3.24
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA (2015) 2.47
Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA (2014) 2.30
Validation of the Social Security Death Index (SSDI): An Important Readily-Available Outcomes Database for Researchers. West J Emerg Med (2008) 2.11
Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol (2007) 2.05
A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J (2007) 2.01
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail (2010) 1.50
New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension (2009) 1.28
Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort. Clin J Am Soc Nephrol (2012) 1.21
A new era for the treatment of hyperkalemia? N Engl J Med (2014) 1.19
Hypokalemia, its contributing factors and renal outcomes in patients with chronic kidney disease. PLoS One (2013) 1.05
Regulation of Potassium Homeostasis. Clin J Am Soc Nephrol (2014) 1.01
Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich) (2004) 0.99
Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease. Am J Nephrol (2015) 0.99
Serum potassium levels and the risk of atrial fibrillation: the Rotterdam Study. Int J Cardiol (2013) 0.88
The relationship between serum potassium, potassium variability and in-hospital mortality in critically ill patients and a before-after analysis on the impact of computer-assisted potassium control. Crit Care (2015) 0.87
Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother (2015) 0.86
Hyperkalemia in Heart Failure. J Am Coll Cardiol (2016) 0.79
An electronic alert to decrease Kayexalate ordering. Ren Fail (2016) 0.78
The Relation of Serum Potassium Concentration with Cardiovascular Events and Mortality in Community-Living Individuals. Clin J Am Soc Nephrol (2017) 0.77
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet (2012) 6.69
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med (2014) 5.93
Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol (2003) 3.09
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation (2005) 2.85
Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension (2006) 2.83
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol (2007) 2.73
Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol (2010) 2.43
The impact of the coronary collateral circulation on mortality: a meta-analysis. Eur Heart J (2011) 2.33
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol (2011) 2.29
Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med (2007) 2.23
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J (2011) 2.14
Implications of geographical variation on clinical outcomes of cardiovascular trials. Am Heart J (2012) 2.06
Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol (2007) 2.05
A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J (2007) 2.01
Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol (2008) 1.97
Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med (2001) 1.88
Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol (2012) 1.87
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol (2013) 1.83
Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension (2009) 1.82
Differences between dialysis modality selection and initiation. Am J Kidney Dis (2012) 1.81
Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant (2008) 1.81
First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int (2005) 1.74
Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. Circulation (2004) 1.73
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med (2005) 1.72
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol (2012) 1.71
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med (2004) 1.69
Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. Clin J Am Soc Nephrol (2010) 1.69
Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail (2012) 1.67
Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail (2008) 1.65
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail (2012) 1.62
Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail (2006) 1.61
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. JACC Cardiovasc Imaging (2009) 1.61
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clin Trials (2012) 1.54
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press (2007) 1.52
Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int (2011) 1.51
Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail (2010) 1.50
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens (2005) 1.49
Comparative analysis of 18-month outcomes and costs of breast reconstruction flap procedures. Plast Reconstr Surg (2014) 1.49
Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial. Eur J Heart Fail (2012) 1.49
ACCF/AHA consensus conference report on professionalism and ethics. Circulation (2004) 1.47
Aldosterone blockade in patients with acute myocardial infarction. Circulation (2003) 1.45
Maximizing scientific knowledge from randomized clinical trials. Am Heart J (2010) 1.42
Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet. Am J Physiol Renal Physiol (2014) 1.41
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail (2013) 1.40
Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial. J Am Coll Cardiol (2003) 1.39
The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol (2003) 1.35
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther (2006) 1.33
Low-density lipoprotein cholesterol in patients with stable coronary heart disease--is it time to shift our goals? N Engl J Med (2005) 1.33
Molecular mechanisms of primary hypercalciuria. J Am Soc Nephrol (2003) 1.33
High heterogeneity within the ribosomal proteins of the Arabidopsis thaliana 80S ribosome. Plant Mol Biol (2005) 1.30
Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. Am Heart J (2005) 1.27
Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation (2002) 1.27
Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J (2011) 1.26
The human coronary collateral circulation: development and clinical importance. Eur Heart J (2013) 1.23
Bone buffering of acid and base in humans. Am J Physiol Renal Physiol (2003) 1.23
Predicting the virulence of MRSA from its genome sequence. Genome Res (2014) 1.23
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol (2005) 1.22
Thiosulfate reduces calcium phosphate nephrolithiasis. J Am Soc Nephrol (2009) 1.21
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med (2013) 1.17
Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press (2007) 1.15
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail (2010) 1.15
Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardiol (2008) 1.14
Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J (2004) 1.13
Mechanism of acid-induced bone resorption. Curr Opin Nephrol Hypertens (2004) 1.11
Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology (2005) 1.09
Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J (2007) 1.09
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press (2008) 1.08
Little D, Nee R, Abbott K, et al. Cost utility analysis of sodium polystyrene sulfate vs. potential alternatives for chronic hyperkalemia. Clinical Nephrology, 2014; 81: 259-268. Clin Nephrol (2015) 1.07
Low serum magnesium and cardiovascular mortality in chronic heart failure: a propensity-matched study. Int J Cardiol (2008) 1.07
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation (2012) 1.06
Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur Heart J (2008) 1.05
Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study. Int J Cardiol (2009) 1.02
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail (2010) 1.02
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J (2012) 1.02
Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol (2009) 1.01
Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). Am Heart J (2002) 1.00
Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming rats. J Bone Miner Res (2004) 1.00
Regulation of renal calcium receptor gene expression by 1,25-dihydroxyvitamin D3 in genetic hypercalciuric stone-forming rats. J Am Soc Nephrol (2005) 0.99
Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Eur J Heart Fail (2011) 0.99
Association of obesity and survival in systolic heart failure after acute myocardial infarction: potential confounding by age. Eur J Heart Fail (2010) 0.99
Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant (2007) 0.99
Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol (2008) 0.99
Calcium oxalate crystal localization and osteopontin immunostaining in genetic hypercalciuric stone-forming rats. Kidney Int (2004) 0.97
A lifetime of prevention: the case of heart failure. Circulation (2002) 0.97
Metabolic acidosis increases intracellular calcium in bone cells through activation of the proton receptor OGR1. J Bone Miner Res (2009) 0.97
Colorectal hepatic metastases: detection with SPIO-enhanced breath-hold MR imaging--comparison of optimized sequences. Radiology (2003) 0.97